HDL, atherosclerosis, and emerging therapies

Cholesterol

Volumn 2013, Issue , 2013, Pages

  Hafiane, Anouar ^a   Genest, Jacques ^b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1 MIMETIC PEPTIDE; APOLIPOPROTEIN A1 MIMETIC PEPTIDE 5A; APOLIPOPROTEIN A1 MIMETIC PEPTIDE 6F; APOLIPOPROTEIN A1 MIMETIC PEPTIDE D 4F; APOLIPOPROTEIN A1 MIMETIC PEPTIDE L 4F; ARI 3037MO; ATI 5261; ATORVASTATIN; CSL 111; CSL 112; DALCETRAPIB; ENDOTHELIAL LIPASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME INHIBITOR; ETC 216; EVACETRAPIB; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LY 248595; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE; PLACEBO; PROTEIN KINASE C BETA; RESERVELOGIX 208; RVX 208; SYNTHETIC PEPTIDE; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABCA1 GENE; ABCG1 GENE; ACUTE CORONARY SYNDROME; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ANTIOXIDANT ACTIVITY; APHERESIS; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; BIOGENESIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL TRANSPORT; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG MEGADOSE; DRUG POTENCY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; GENE; GENE MUTATION; GENE THERAPY; GENETIC ASSOCIATION; HEART INFARCTION; HEART PROTECTION; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOTENSION; INCIDENCE; LIPOPROTEIN METABOLISM; LIVER TOXICITY; LOW DRUG DOSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC SCLEROSIS; ULTRACENTRIFUGATION; UNSPECIFIED SIDE EFFECT;

EID: 84879373355     PISSN: 20901283     EISSN: 20901291     Source Type: Journal    
DOI: 10.1155/2013/891403     Document Type: Review

References (173)

1. Rader D. J., deGoma E. M., Approach to the patient with extremely low HDL-cholesterol. The Journal of Clinical Endocrinology & Metabolism 2012 97 10 3399 3407
2. Rader D. J., Tall A. R., The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis? Nature Medicine 2012 18 9 1344 1346
3. Baigent C., Blackwell L., Emberson J., Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. The Lancet 2010 376 9753 1670 1681
4. Boden W. E., Probstfield J. L., Anderson T., Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine 2011 365 24 2255 2267
5. Rosenson R. S., Gotto Jr. A. M., When clinical trials fail to address treatment gaps: the failure of niacin-laropiprant to reduce cardiovascular events. Current Atherosclerosis Reports 2013 15 6, article 332 10.1007/s11883-013-0332-x
6. Besler C., Heinrich K., Rohrer L., Doerries C., Riwanto M., Shih D. M., Chroni A., Yonekawa K., Stein S., Schaefer N., Mueller M., Akhmedov A., Daniil G., Manes C., Templin C., Wyss C., Maier W., Tanner F. C., Matter C. M., Corti R., Furlong C., Lusis A. J., Von Eckardstein A., Fogelman A. M., Lüscher T. F., Landmesser U., Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. Journal of Clinical Investigation 2011 121 7 2693 2708 2-s2.0-79959919890 10.1172/JCI42946
7. Rosenson R. S., Brewer H. B. Jr., Chapman M. J., Fazio S., Hussain M. M., Kontush A., Krauss R. M., Otvos J. D., Remaley A. T., Schaefer E. J., HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clinical Chemistry 2011 57 3 392 410 2-s2.0-79952222810 10.1373/clinchem.2010.155333
8. Niesor E. J., Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Current Opinion in Lipidology 2011 22 4 288 295 2-s2.0-79960648677 10.1097/MOL.0b013e3283475e00
9. Delalla O. F., Elliot H. A., Gofman J. W., Ultracentrifugal studies of high density serum lipoproteins in clinically healthy adults. The American Journal of Physiology 1954 179 2 333 337 2-s2.0-0001297463
10. Fruchart J. C., Bard J. M., Lipoprotein particle measurement: an alternative approach to classification of lipid disorders. Current Opinion in Lipidology 1991 2 6 362 366 2-s2.0-0026018175
11. Camont L., Chapman M. J., Kontush A., Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends in Molecular Medicine 2011 17 10 594 603 10.1016/j.molmed.2011.05.013
12. Heinecke J. W., The HDL proteome: a marker-and perhaps mediator-of coronary artery disease. Journal of Lipid Research 2009 50, supplement S167 S171 2-s2.0-66349096057 10.1194/jlr.R800097-JLR200
13. Davidson W. S., Silva R. A. G. D., Chantepie S., Lagor W. R., Chapman M. J., Kontush A., Proteomic analysis of defined hdl subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 6 870 876 2-s2.0-66349083560 10.1161/ATVBAHA.109.186031
14. Superko H. R., Pendyala L., Williams P. T., Momary K. M., King S. B. III, Garrett B. C., High-density lipoprotein subclasses and their relationship to cardiovascular disease. Journal of Clinical Lipidology 2012 6 6 496 523
15. Khera A. V., Rader D. J., Future therapeutic directions in reverse cholesterol transport. Current Atherosclerosis Reports 2010 12 1 73 81 2-s2.0-77149158139 10.1007/s11883-009-0080-0
16. Ansell B. J., Navab M., Hama S., Kamranpour N., Fonarow G., Hough G., Rahmani S., Mottahedeh R., Dave R., Reddy S. T., Fogelman A. M., Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003 108 22 2751 2756 2-s2.0-10744224101 10.1161/01.CIR.0000103624.14436.4B
17. Di Angelantonio E., Sarwar N., Perry P., Kaptoge S., Ray K. K., Thompson A., Wood A. M., Lewington S., Sattar N., Packard C. J., Collins R., Thompson S. G., Danesh J., Major lipids, apolipoproteins, and risk of vascular disease. Journal of the American Medical Association 2009 302 18 1993 2000 2-s2.0-70450081001 10.1001/Journal of the American Medical Association.2009.1619
18. Mackey R. H., Greenland P., Goff D. C. Jr., Lloyd-Jones D., Sibley C. T., Mora S., High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). Journal of the American College of Cardiology 2012 60 6 508 516
19. Ginsberg H. N., Elam M. B., Lovato L. C., Effects of combination lipid therapy in type 2 diabetes mellitus. New England Journal of Medicine 2010 362 17 1563 1574
20. Jun M., Foote C., Lv J., Neal B., Patel A., Nicholls S. J., Grobbee D. E., Cass A., Chalmers J., Perkovic V., Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. The Lancet 2010 375 9729 1875 1884 2-s2.0-77952708442 10.1016/S0140-6736(10)60656-3
21. Fruchart J. C., Sacks F., Hermans M. P., Assmann G., Brown W. V., Ceska R., Chapman M. J., Dodson P. M., Fioretto P., Ginsberg H. N., Kadowaki T., Lablanche J. M., Marx N., Plutzky J., Reiner Ž., Rosenson R. S., Staels B., Stock J. K., Sy R., Wanner C., Zambon A., Zimmet P., The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. American Journal of Cardiology 2008 102 10, supplement 1K 34K 2-s2.0-56349154187 10.1016/j.amjcard.2008.10.002
22. Arsenault B. J., Barter P., DeMicco D. A., TNT Study Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. Journal of the American College of Cardiology 2011 57 1 63 69
23. van der Steeg W. A., Holme I., Boekholdt S. M., Larsen M. L., Lindahl C., Stroes E. S. G., Tikkanen M. J., Wareham N. J., Faergeman O., Olsson A. G., Pedersen T. R., Khaw K. T., Kastelein J. J. P., High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. Journal of the American College of Cardiology 2008 51 6 634 642 2-s2.0-38749102779 10.1016/j.jacc.2007.09.060
24. Barter P., Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial. American Journal of Cardiology 2009 104 10 2-s2.0-71749117559 10.1016/j.amjcard.2009.09.014
25. Barter P. J., Caulfield M., Eriksson M., ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine 2007 357 21 2109 2122
26. Ridker P. M., Genest J., Boekholdt S. M., Libby P., Gotto A. M., Nordestgaard B. G., Mora S., MacFadyen J. G., Glynn R. J., Kastelein J. J. P., HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. The Lancet 2010 376 9738 333 339 2-s2.0-77955712458 10.1016/S0140-6736(10)60713-1
27. Schwartz G. G., Olsson A. G., Abt M., dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. New England Journal of Medicine 2012 367 22 2089 2099
28. HPS2-THRIVE Collaborative Group, HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal 2013 34 17 1279 1291
29. Cook C., Sheets C., Clinical equipoise and personal equipoise: two necessary ingredients for reducing bias in manual therapy trials. Journal of Manual and Manipulative Therapy 2011 19 1 55 57 2-s2.0-79952411078 10.1179/106698111X12899036752014
30. Frikke-Schmidt R., Nordestgaard B. G., Schnohr P., Tybjærg-Hansen A., Single nucleotide polymorphism in the low-density lipoprotein receptor is associated with a threefold risk of stroke: a case-control and prospective study. European Heart Journal 2004 25 11 943 951 2-s2.0-3042752268 10.1016/j.ehj.2004.03.020
31. Voight B. F., Peloso G.M., Orho-Melander M., Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet 2012 380 9841 572 580
32. Glomset J. A., The plasma lecithins:cholesterol acyltransferase reaction. Journal of Lipid Research 1968 9 2 155 167 2-s2.0-0014264541
33. Devries-Seimon T., Li Y., Pin M. Y., Stone E., Wang Y., Davis R. J., Flavell R., Tabas I., Cholesterol-induced macrophage apoptosis requires ER stress pathways and engagement of the type A scavenger receptor. Journal of Cell Biology 2005 171 1 61 73 2-s2.0-26444524411 10.1083/jcb.200502078
34. Khera A. V., Cuchel M., De La Llera-Moya M., Rodrigues A., Burke M. F., Jafri K., French B. C., Phillips J. A., Mucksavage M. L., Wilensky R. L., Mohler E. R., Rothblat G. H., Rader D. J., Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. New England Journal of Medicine 2011 364 2 127 135 2-s2.0-78651379500
35. Hassan H. H., Denis M., Lee D. Y. D., Iatan I., Nyholt D., Ruel I., Krimbou L., Genest J., Identification of an ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL formation: implications for current models of HDL biogenesis. Journal of Lipid Research 2007 48 11 2428 2442 2-s2.0-35848942798 10.1194/jlr.M700206-JLR200
36. Rosenson R. S., Brewer H. B. Jr., Davidson W. S., Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012 125 15 1905 1919
37. Rothblat G. H., Phillips M. C., High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Current Opinion in Lipidology 2010 21 3 229 238 2-s2.0-77952357848 10.1097/MOL.0b013e328338472d
38. Adorni M. P., Zimetti F., Billheimer J. T., Wang N., Rader D. J., Phillips M. C., Rothblat G. H., The roles of different pathways in the release of cholesterol from macrophages. Journal of Lipid Research 2007 48 11 2453 2462 2-s2.0-35848954726 10.1194/jlr.M700274-JLR200
39. Oram J. F., Vaughan A. M., ABCA1-mediated transport of cellular cholesterol and phospholipids to HBL apolipoproteins. Current Opinion in Lipidology 2000 11 3 253 260 2-s2.0-0034115889 10.1097/00041433-200006000-00005
40. Nagao K., Tomioka M., Ueda K., Function and regulation of ABCA1-membrane meso-domain organization and reorganization. FEBS Journal 2011 278 18 3190 3203 10.1111/j.1742-4658.2011.08170.x.
41. Zhao Y., Van Berkel T. J. C., Van Eck M., Relative roles of various efflux pathways in net cholesterol efflux from macrophage foam cells in atherosclerotic lesions. Current Opinion in Lipidology 2010 21 5 441 453 2-s2.0-77957569778 10.1097/MOL.0b013e32833dedaa
42. Sorci-Thomas M. G., Owen J. S., Fulp B., Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. Journal of Lipid Research 2012 53 9 1890 1909
43. Phillips M. C., New insights into the determination of HDL structure by apolipoproteins. Journal of Lipid Research 2012
44. Okuhira K., Fitzgerald M. L., Tamehiro N., Ohoka N., Suzuki K., Sawada J. I., Naito M., Nishimaki-Mogami T., Binding of PDZ-RhoGEF to ATP-binding cassette transporter A1 (ABCA1) induces cholesterol efflux through RhoA activation and prevention of transporter degradation. Journal of Biological Chemistry 2010 285 21 16369 16377 2-s2.0-77952338862 10.1074/jbc.M109.061424
45. Neufeld E. B., Remaley A. T., Demosky S. J., Stonik J. A., Cooney A. M., Comly M., Dwyer N. K., Zhang M., Blanchette-Mackie J., Santamarina-Fojo S., Brewer H. B., Cellular localization and trafficking of the human ABCA1 transporter. Journal of Biological Chemistry 2001 276 29 27584 27590 2-s2.0-0035920220 10.1074/jbc.M103264200
46. Kellner-Weibel G., de la Llera-Moya M., Update on HDL receptors and cellular cholesterol transport. Current Atherosclerosis Reports 2011 13 3 233 241 10.1007/s11883-011-0169-0
47. Timmins J. M., Lee J. Y., Boudyguina E., Kluckman K. D., Brunham L. R., Mulya A., Gebre A. K., Coutinho J. M., Colvin P. L., Smith T. L., Hayden M. R., Maeda N., Parks J. S., Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. Journal of Clinical Investigation 2005 115 5 1333 1342 2-s2.0-20944435724 10.1172/JCI200523915
48. Brunham L. R., Kruit J. K., Iqbal J., Fievet C., Timmins J. M., Pape T. D., Coburn B. A., Bissada N., Staels B., Groen A. K., Hussain M. M., Parks J. S., Kuipers F., Hayden M. R., Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. Journal of Clinical Investigation 2006 116 4 1052 1062 2-s2.0-33645502340 10.1172/JCI27352
49. Zhang Y., McGillicuddy F. C., Hinkle C. C., O'Neill S., Glick J. M., Rothblat G. H., Reilly M. P., Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 2010 121 11 1347 1355 2-s2.0-77949780930 10.1161/CIRCULATIONAHA.109.897330
50. Fernández-Hernando C., Suárez Y., Rayner K. J., Moore K. J., MicroRNAs in lipid metabolism. Current Opinion in Lipidology 2011 22 2 86 92
51. Rayner K. J., Sheedy F. J., Esau C. C., Hussain F. N., Temel R. E., Parathath S., Van Gils J. M., Rayner A. J., Chang A. N., Suarez Y., Fernandez-Hernando C., Fisher E. A., Moore K. J., Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. Journal of Clinical Investigation 2011 121 7 2921 2931 2-s2.0-79960015327 10.1172/JCI57275
52. Rayner K. J., Esau C. C., Hussain F. N., Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011 478 7369 404 407
53. Oosterveer M. H., Grefhorst A., Groen A. K., Kuipers F., The liver X receptor: control of cellular lipid homeostasis and beyond: implications for drug design. Progress in Lipid Research 2010 49 4 343 352 2-s2.0-77956365905 10.1016/j.plipres.2010.03.002
54. De La Llera-Moya M., Drazul-Schrader D., Asztalos B. F., Cuchel M., Rader D. J., Rothblat G. H., The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 4 796 801 2-s2.0-77950894330 10.1161/ATVBAHA.109.199158
55. Akiyama T. E., Sakai S., Lambert G., Nicol C. J., Matsusue K., Pimprale S., Lee Y. H., Ricote M., Glass C. K., Brewer H. B., Gonzalez F. J., Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Molecular and Cellular Biology 2002 22 8 2607 2619 2-s2.0-0036205326 10.1128/MCB.22.8.2607-2619.2002
56. Rayner K. J., Surez Y., Dvalos A., MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010 328 5985 1570 1573
57. Gelissen I. C., Cartland S., Brown A. J., Sandoval C., Kim M., Dinnes D. L., Lee Y., Hsieh V., Gaus K., Kritharides L., Jessup W., Expression and stability of two isoforms of ABCG1 in human vascular cells. Atherosclerosis 2010 208 1 75 82 2-s2.0-73449097086 10.1016/j.atherosclerosis.2009.06.028
58. Kerr I. D., Haider A. J., Gelissen I. C., The ABCG family of membrane-associated transporters: you don't have to be big to be mighty. British Journal of Pharmacology 2011 164 7 1767 1779
59. Tarling E. J., Bojanic D. D., Tangirala R. K., Wang X., Lovgren-Sandblom A., Lusis A. J., Bjorkhem I., Edwards P. A., Impaired development of atherosclerosis in Abcg1-/- Apoe -/- mice: identification of specific oxysterols that both accumulate in Abcg1-/- Apoe-/- tissues and induce apoptosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 6 1174 1180 2-s2.0-77952885753 10.1161/ATVBAHA.110.205617
60. Kennedy M. A., Barrera G. C., Nakamura K., Baldán Á., Tarr P., Fishbein M. C., Frank J., Francone O. L., Edwards P. A., ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metabolism 2005 1 2 121 131 2-s2.0-20144381320 10.1016/j.cmet.2005.01.002
61. Yvan-Charvet L., Wang N., Tall A. R., Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 2 139 143 2-s2.0-75149124430 10.1161/ATVBAHA.108.179283
62. Van Eck M., Bos I. S. T., Hildebrand R. B., Van Rij B. T., Van Berkel T. J. C., Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. American Journal of Pathology 2004 165 3 785 794 2-s2.0-4344574038
63. Demetz E., Tancevski I., Duwensee K., Inhibition of hepatic scavenger receptor-class B type I by RNA interference decreases atherosclerosis in rabbits. Atherosclerosis 2012 222 2 360 366
64. Vergeer M., Korporaal S. J. A., Franssen R., Meurs I., Out R., Hovingh G. K., Hoekstra M., Sierts J. A., Dallinga-Thie G. M., Motazacker M. M., Holleboom A. G., Van Berkel T. J. C., Kastelein J. J. P., Van Eck M., Kuivenhoven J. A., Genetic variant of the scavenger receptor BI in humans. New England Journal of Medicine 2011 364 2 136 145 2-s2.0-78651352098
65. Al-Jarallah A., Trigatti B. L., A role for the scavenger receptor, class B type I in high density lipoprotein dependent activation of cellular signaling pathways. Biochimica et Biophysica Acta 2010 1801 12 1239 1248 2-s2.0-77957941762 10.1016/j.bbalip.2010.08.006
66. Wang X., Collins H. L., Ranalletta M., Fuki I. V., Billheimer J. T., Rothblat G. H., Tall A. R., Rader D. J., Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. Journal of Clinical Investigation 2007 117 8 2216 2224 2-s2.0-34547700634 10.1172/JCI32057
67. Hildebrand R. B., Lammers B., Meurs I., Korporaal S. J. A., De Haan W., Zhao Y., Kruijt J. K., Praticò D., Schimmel A. W. M., Holleboom A. G., Hoekstra M., Kuivenhoven J. A., Van Berkel T. J. C., Rensen P. C. N., Van Eck M., Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B Type i (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 7 1439 1445 2-s2.0-77953962720 10.1161/ATVBAHA.110.205153
68. El Bouhassani M., Gilibert S., Moreau M., Saint-Charles F., Tréguier M., Poti F., Chapman M. J., Le Goff W., Lesnik P., Huby T., Cholesteryl ester transfer protein expression partially attenuates the adverse effects of SR-BI receptor deficiency on cholesterol metabolism and atherosclerosis. Journal of Biological Chemistry 2011 286 19 17227 17238 2-s2.0-79955771069 10.1074/jbc.M111.220483
69. Masson D., Koseki M., Ishibashi M., Larson C. J., Miller S. G., King B. D., Tall A. R., Increased HDL cholesterol and ApoA-I in humans and mice treated with a novel SR-BI inhibitor. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 12 2054 2060 2-s2.0-73849098682 10.1161/ATVBAHA.109.191320
70. Navab M., Reddy S. T., Van Lenten B. J., Fogelman A. M., HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nature Reviews Cardiology 2011 8 4 222 232 2-s2.0-79953192995 10.1038/nrcardio.2010.222
71. Besler C., Lüscher T. F., Landmesser U., Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Molecular Medicine 2012 4 4 251 268
72. Kontush A., Chapman M. J., Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Current Opinion in Lipidology 2010 21 4 312 318 2-s2.0-77954956885 10.1097/MOL.0b013e32833bcdc1
73. Sorrentino S. A., Besler C., Rohrer L., Meyer M., Heinrich K., Bahlmann F. H., Mueller M., Horváth T., Doerries C., Heinemann M., Flemmer S., Markowski A., Manes C., Bahr M. J., Haller H., Von Eckardstein A., Drexler H., Landmesser U., Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010 121 1 110 122 2-s2.0-74549172922 10.1161/CIRCULATIONAHA.108.836346
74. Navab M., Hama S. Y., Hough G. P., Subbanagounder G., Reddy S. T., Fogelman A. M., A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. Journal of Lipid Research 2001 42 8 1308 1317 2-s2.0-0034891279
75. Liu Y., Tang C., Regulation of ABCA1 functions by signaling pathways. Biochimica et Biophysica Acta 2012 1821 3 522 529
76. Patel S., Di Bartolo B. A., Nakhla S., Heather A. K., Mitchell T. W., Jessup W., Celermajer D. S., Barter P. J., Rye K. A., Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis 2010 212 2 392 397 2-s2.0-77957703075 10.1016/j.atherosclerosis.2010.05.035
77. Riwanto M., Rohrer L., Roschitzki B., Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 2013 127 8 891 904
78. Sato K., Okajima F., Role of sphingosine 1-phosphate in anti-atherogenic actions of high-density lipoprotein. World Journal of Biological Chemistry 2010 1 11 327 337
79. Alwaili K., Bailey D., Awan Z., The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochimica et Biophysica Acta 2012 1821 3 405 415
80. Mineo C., Yuhanna I. S., Quon M. J., Shaul P. W., High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. Journal of Biological Chemistry 2003 278 11 9142 9149 2-s2.0-0038322055 10.1074/jbc.M211394200
81. Suc I., Escargueil-Blanc I., Troly M., Salvayre R., Negre-Salvayre A., HDL and apoA prevent cell death of endothelial cells induced by oxidized LDL. Arteriosclerosis, Thrombosis, and Vascular Biology 1997 17 10 2158 2166 2-s2.0-0031455505
82. Langmann T., Klucken J., Reil M., Liebisch G., Luciani M. F., Chimini G., Kaminski W. E., Schmitz G., Molecular cloning of the human ATP-Binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochemical and Biophysical Research Communications 1999 257 1 29 33 2-s2.0-0033515841 10.1006/bbrc.1999.0406
83. Nofer J. R., Brodde M. F., Kehrel B. E., High-density lipoproteins, platelets and the pathogenesis of atherosclerosis: frontiers in research review: physiological and pathological functions of high-density lipoprotein. Clinical and Experimental Pharmacology and Physiology 2010 37 7 726 735 2-s2.0-77953865873 10.1111/j.1440-1681.2010.05377.x
84. Li Y., Dong J. B., Wu M. P., Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice. European Journal of Pharmacology 2008 590 1-3 417 422 2-s2.0-48049092375 10.1016/j.ejphar.2008.06.047
85. Figueirêdo P. M. S., Catani C. F., Yano T., Serum high-density lipoprotein (HDL) inhibits in vitro enterohemolysin (EHly) activity produced by enteropathogenic Escherichia coli. FEMS Immunology and Medical Microbiology 2003 38 1 53 57 2-s2.0-0142124413 10.1016/S0928-8244(03)00125-1
86. Yin K., Tang S. L., Yu X. H., Apolipoprotein A-I inhibits LPS-induced atherosclerosis in ApoE-/- mice possibly via activated STAT3-mediated upregulation of tristetraprolin. Acta Pharmacologica Sinica 2013 10.1038/aps.2013.10
87. Hager K. M., Hajduk S. L., Mechanism of resistance of African trypanosomes to cytotoxic human HDL. Nature 1997 385 6619 823 826 2-s2.0-0031048412 10.1038/385823a0
88. Krishna R., Anderson M. S., Bergman A. J., Jin B., Fallon M., Cote J., Rosko K., Chavez-Eng C., Lutz R., Bloomfield D. M., Gutierrez M., Doherty J., Bieberdorf F., Chodakewitz J., Gottesdiener K. M., Wagner J. A., Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. The Lancet 2007 370 9603 1907 1914 2-s2.0-36549078679 10.1016/S0140-6736(07) 61813-3
89. Chapman M. J., Le Goff W., Guerin M., Kontush A., Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. European Heart Journal 2010 31 2 149 164 2-s2.0-74549148035 10.1093/eurheartj/ ehp399
90. Cannon C. P., Shah S., Dansky H. M., Safety of anacetrapib in patients with or at high risk for coronary heart disease. New England Journal of Medicine 2010 363 25 2406 2415
91. Lauring B., Taggart A. K., Tata J. R., Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Science Translational Medicine 2012 4 148 148ra115
92. Clinical trial.gov.REVEAL: Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification, 2010, http://clinicaltrials.gov/ct2/ show/NCT01252953
93. Nicholls S. J., Brewer H. B., Kastelein J. J., Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. Journal of the American Medical Association 2011 306 19 2099 2109
94. http://clinicaltrials.gov/show/NCT01687998
95. Carlson L. A., Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. Journal of Internal Medicine 2005 258 2 94 114 2-s2.0-22644437126 10.1111/j.1365-2796.2005.01528.x
96. Wierzbicki A. S., Niacin: the only vitamin that reduces cardiovascular events. International Journal of Clinical Practice 2011 65 4 379 385
97. Clofibrate and niacin in coronary heart disease. Journal of the American Medical Association 1975 231 4 360 381
98. Bruckert E., Labreuche J., Amarenco P., Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010 210 2 353 361 2-s2.0-77952397461 10.1016/j.atherosclerosis.2009.12.023
99. Cannon C. P., High-density lipoprotein cholesterol as the Holy Grail. Journal of the American Medical Association 2011 306 19 2153 2155
100. Gouni-Berthold I., Berthold H. K., The role of Niacin in lipid-lowering treatment: are we aiming too high? Current Pharmaceutical Design 2013 19 17 3094 3106
101. Parson H. K., Harati H., Cooper D., Vinik A. I., The role of prostaglandin D2 and the autonomic nervous system on Niacin induced flushing. Journal of Diabetes 2013 5 1 59 67
102. Bays H. E., Shah A., Dong Q., McCrary Sisk C., Maccubbin D., Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. International Journal of Clinical Practice 2011 65 4 436 445 2-s2.0-79952745060 10.1111/j.1742-1241.2010.02620.x
103. http://www.arisaph.com/newsroom/press.php
104. Sirtori C. R., Calabresi L., Franceschini G., Baldassarre D., Amato M., Johansson J., Salvetti M., Monteduro C., Zulli R., Muiesan M. L., Agabiti-Rosei E., Cardiovascular status of carriers of the apolipoprotein A-IMilano mutant: the limone sul garda study. Circulation 2001 103 15 1949 1954 2-s2.0-0035901577
105. Nissen S. E., Tsunoda T., Tuzcu E. M., Schoenhagen P., Cooper C. J., Yasin M., Eaton G. M., Lauer M. A., Sheldon W. S., Grines C. L., Halpern S., Crowe T., Blankenship J. C., Kerensky R., Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. Journal of the American Medical Association 2003 290 17 2292 2300 2-s2.0-0242577955 10.1001/Journal of the American Medical Association.290.17.2292
106. United States Securities and Exchange Commission filing, 2013, http://www.faqs.org/sec-filings/091224/MEDICINES-CO-DE-8-K
107. Tardif J. C., Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology? Journal of Clinical Lipidology 2010 4 5 399 404 2-s2.0-77957884737 10.1016/j.jacl.2010.08.018
108. Ibanez B., Giannarelli C., Cimmino G., Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis 2012 220 1 72 77
109. Chenevard R., Hürlimann D., Spieker L., Reconstituted HDL in acute coronary syndromes. Cardiovascular Therapeutics 2012 30 2 e51 e57
110. A single ascending dose study examining the safety and pharmacokinetic profile of reconstituted high density lipoprotein (CSL112) administered to patients. In: ClinicalTrials.gov. National Library of Medicine. 2012, http://www.clinicaltrials.gov/ct2/show/NCT01499420
111. Waksman R., Torguson R., Kent K. M., Pichard A. D., Suddath W. O., Satler L. F., Martin B. D., Perlman T. J., Maltais J. A. B., Weissman N. J., Fitzgerald P. J., Brewer H. B., A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. Journal of the American College of Cardiology 2010 55 24 2727 2735 2-s2.0-77953107241 10.1016/j.jacc.2009.12.067
112. Sacks F. M., Rudel L. L., Conner A., Akeefe H., Kostner G., Baki T., Rothblat G., de la Llera-Moya M., Asztalos B., Perlman T., Zheng C., Alaupovic P., Maltais J. A. B., Brewer H. B., Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. Journal of Lipid Research 2009 50 5 894 907 2-s2.0-67649675003 10.1194/jlr.M800622-JLR200
113. Anantharamaiah G. M., Jones J. L., Brouillette C. G., Studies of synthetic peptide analogs of the amphiphatic helix. Structure of complexes with dimyristoyl phosphatidylcholine. Journal of Biological Chemistry 1985 260 18 10248 10255 2-s2.0-0022353001
114. Smith J. D., Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Current Opinion in Investigational Drugs 2010 11 9 989 996 2-s2.0-77956244457
115. Datta G., Chaddha M., Hama S., Navab M., Fogelman A. M., Garber D. W., Mishra V. K., Epand R. M., Epand R. F., Lund-Katz S., Phillips M. C., Segrest J. P., Anantharamaiah G. M., Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. Journal of Lipid Research 2001 42 7 1096 1104 2-s2.0-0034947950
116. Shah P. K., Chyu K. Y., Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management. Trends in Cardiovascular Medicine 2005 15 8 291 296 2-s2.0-27744543480 10.1016/j.tcm.2005.09.003
117. Weihrauch D., Xu H., Shi Y., Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. American Journal of Physiology 2007 293 H1432 H1441
118. Bloedon L. T., Dunbar R., Duffy D., Pinell-Salles P., Norris R., DeGroot B. J., Movva R., Navab M., Fogelman A. M., Rader D. J., Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. Journal of Lipid Research 2008 49 6 1344 1352 2-s2.0-48549103014 10.1194/jlr.P800003-JLR200
119. Sherman C. B., Peterson S. J., Frishman W. H., Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiology in Review 2010 18 3 141 147 2-s2.0-77951492263 10.1097/CRD. 0b013e3181c4b508
120. Navab M., Shechter I., Anantharamaiah G. M., Reddy S. T., Van Lenten B. J., Fogelman A. M., Structure and function of HDL mimetics. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 2 164 168 2-s2.0-75149146582 10.1161/ATVBAHA.109.187518
121. Watson C. E., Weissbach N., Kjems L., Ayalasomayajula S., Zhang Y., Chang I., Navab M., Hama S., Hough G., Reddy S. T., Soffer D., Rader D. J., Fogelman A. M., Schecter A., Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. Journal of Lipid Research 2011 52 2 361 373 2-s2.0-78751496188 10.1194/jlr.M011098
122. Ou J., Ou Z., Jones D. W., Holzhauer S., Hatoum O. A., Ackerman A. W., Weihrauch D. W., Gutterman D. D., Guice K., Oldham K. T., Hillery C. A., Pritchard K. A., L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003 107 18 2337 2341 2-s2.0-0037986617 10.1161/01.CIR.0000070589.61860.A9
123. Chen X., Burton C., Song X., Mcnamara L., Langella A., Cianetti S., Chang C. H., Wang J., An apoa-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration. International Journal of Biological Sciences 2009 5 5 489 499 2-s2.0-70350441792
124. Navab M., Reddy S. T., Anantharamaiah G. M., Imaizumi S., Hough G., Hama S., Fogelman A. M., Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. Journal of Lipid Research 2011 52 6 1200 1210 2-s2.0-79955986984 10.1194/jlr.M013144
125. Navab M., Reddy S. T., Anantharamaiah G. M., D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in lowdensity lipoprotein receptor-null mice. Journal of Lipid Research 2012 53 437 445
126. Remaley A. T., Thomas F., Stonik J. A., Demosky S. J., Bark S. E., Neufeld E. B., Bocharov A. V., Vishnyakova T. G., Patterson A. P., Eggerman T. L., Santamarina-Fojo S., Brewer H. B., Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. Journal of Lipid Research 2003 44 4 828 836 2-s2.0-10744232793 10.1194/jlr.M200475-JLR200
127. Anantharamaiah G. M., Mishra V. K., Garber D. W., Datta G., Handattu S. P., Palgunachari M. N., Chaddha M., Navab M., Reddy S. T., Segrest J. P., Fogelman A. M., Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. Journal of Lipid Research 2007 48 9 1915 1923 2-s2.0-34548439900 10.1194/jlr.R700010-JLR200
128. Chattopadhyay A., Navab M., Hough G., A novel approach to oral ApoA-I mimetic therapy. Journal of Lipid Research 2013 54 4 995 1010
129. Imaizumi S., Navab M., Morgantini C., Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins. Circulation Journal 2011 75 7 1533 1538 10.1253/circj.CJ-11-0460
130. Tabet F., Remaley A. T., Segaliny A. I., Millet J., Yan L., Nakhla S., Barter P. J., Rye K. A., Lambert G., The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 2 246 252 2-s2.0-75149191408 10.1161/ATVBAHA.109.200196
131. Carballo-Jane E., Chen Z., O'Neill E., Wang J., Burton C., Chang C. H., Chen X., Eveland S., Frantz-Wattley B., Gagen K., Hubbard B., Ichetovkin M., Luell S., Meurer R., Song X., Strack A., Langella A., Cianetti S., Rech F., Capit E., Bufali S., Veneziano M., Verdirame M., Bonelli F., Monteagudo E., Pessi A., Ingenito R., Bianchi E., ApoA-I mimetic peptides promote pre- β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose. Bioorganic and Medicinal Chemistry 2010 18 24 8669 8678 2-s2.0-78649445873 10.1016/j.bmc.2010.09.074
132. Zheng Y., Patel A. B., Narayanaswami V., Hura G. L., Hang B., Bielicki J. K., HDL mimetic peptide ATI-5261 forms an oligomeric assembly in solution that dissociates to monomers upon dilution. Biochemistry 2011 50 19 4068 4076 2-s2.0-79955867694 10.1021/bi2002955
133. Bielicki J. K., Zhang H., Cortez Y., Zheng Y., Narayanaswami V., Patel A., Johansson J., Azhar S., A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. Journal of Lipid Research 2010 51 6 1496 1503 2-s2.0-77952737056 10.1194/jlr.M003665
134. http://circ.ahajournals.org/cgi/content/meeting
135. Edmondson A. C., Brown R. J., Kathiresan S., Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. The Journal of Clinical Investigation 2009 119 4 1042 1050 10.1172/JCI37176
136. Badellino K. O., Wolfe M. L., Reilly M. P., Rader D. J., Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Medicine 2006 3 2, article e22 2-s2.0-33644842749 10.1371/journal.pmed.0030022
137. Tang N. P., Wang L. S., Yang L., Zhou B., Gu H. J., Sun Q. M., Cong R. H., Zhu H. J., Wang B., Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population. Journal of Lipid Research 2008 49 2 369 375 2-s2.0-38949176388 10.1194/jlr.M700399-JLR200
138. Ishida T., Choi S., Kundu R. K., Hirata K. I., Rubin E. M., Cooper A. D., Quertermous T., Endothelial lipase is a major determinant of HDL level. Journal of Clinical Investigation 2003 111 3 347 355 2-s2.0-0037314398 10.1172/JCI200316306
139. deGoma E. M., Rader D. J., Novel HDL-directed pharmacotherapeutic strategies. Nature Reviews Cardiology 2011 8 5 266 277
140. Brown R. J., Lagor W. R., Sankaranaravanan S., Yasuda T., Quertermous T., Rothblat G. H., Rader D. J., Impact of combined deficiency of hepatic lipase and endothelial lipase on the metabolism of both high-density lipoproteins and apolipoprotein b-containing lipoproteins. Circulation Research 2010 107 3 357 364 2-s2.0-77956628427 10.1161/CIRCRESAHA.110.219188
141. Goodman K. B., Bury M. J., Cheung M., Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors. Bioorganic & Medicinal Chemistry Letters 2009 19 1 27 30
142. O'Connell D. P., LeBlanc D. F., Cromley D., Billheimer J., Rader D. J., Bachovchin W. W., Design and synthesis of boronic acid inhibitors of endothelial lipase. Bioorganic & Medicinal Chemistry Letters 2012 22 3 1397 1401
143. Teslovich T. M., Musunuru K., Smith A. V., Edmondson A. C., Stylianou I. M., Koseki M., Pirruccello J. P., Ripatti S., Chasman D. I., Willer C. J., Johansen C. T., Fouchier S. W., Isaacs A., Peloso G. M., Barbalic M., Ricketts S. L., Bis J. C., Aulchenko Y. S., Thorleifsson G., Feitosa M. F., Chambers J., Orho-Melander M., Melander O., Johnson T., Li X., Guo X., Li M., Shin Cho Y., Jin Go M., Jin Kim Y., Lee J. Y., Park T., Kim K., Sim X., Twee-Hee Ong R., Croteau-Chonka D. C., Lange L. A., Smith J. D., Song K., Hua Zhao J., Yuan X., Luan J., Lamina C., Ziegler A., Zhang W., Zee R. Y. L., Wright A. F., Witteman J. C. M., Wilson J. F., Willemsen G., Wichmann H. E., Whitfield J. B., Waterworth D. M., Wareham N. J., Waeber G., Vollenweider P., Voight B. F., Vitart V., Uitterlinden A. G., Uda M., Tuomilehto J., Thompson J. R., Tanaka T., Surakka I., Stringham H. M., Spector T. D., Soranzo N., Smit J. H., Sinisalo J., Silander K., Sijbrands E. J. G., Scuteri A., Scott J., Schlessinger D., Sanna S., Salomaa V., Saharinen J., Sabatti C., Ruokonen A., Rudan I., Rose L. M., Roberts R., Rieder M., Psaty B. M., Pramstaller P. P., Pichler I., Perola M., Penninx B. W. J. H., Pedersen N. L., Pattaro C., Parker A. N., Pare G., Oostra B. A., O'donnell C. J., Nieminen M. S., Nickerson D. A., Montgomery G. W., Meitinger T., Mcpherson R., Mccarthy M. I., Mcardle W., Masson D., Martin N. G., Marroni F., Mangino M., Magnusson P. K. E., Lucas G., Luben R., Loos R. J. F., Lokki M. L., Lettre G., Langenberg C., Launer L. J., Lakatta E. G., Laaksonen R., Kyvik K. O., Kronenberg F., König I. R., Khaw K. T., Kaprio J., Kaplan L. M., Johansson Å., Jarvelin M. R., Cecile A., Ingelsson E., Igl W., Kees Hovingh G., Hottenga J. J., Hofman A., Hicks A. A., Hengstenberg C., Heid I. M., Hayward C., Havulinna A. S., Hastie N. D., Harris T. B., Haritunians T., Hall A. S., Gyllensten U., Guiducci C., Groop L. C., Gonzalez E., Gieger C., Freimer N. B., Ferrucci L., Erdmann J., Elliott P., Ejebe K. G., Döring A., Dominiczak A. F., Demissie S., Deloukas P., De Geus E. J. C., De Faire U., Crawford G., Collins F. S., Chen Y. D. I., Caulfield M. J., Campbell H., Burtt N. P., Bonnycastle L. L., Boomsma D. I., Boekholdt S. M., Bergman R. N., Barroso I., Bandinelli S., Ballantyne C. M., Assimes T. L., Quertermous T., Altshuler D., Seielstad M., Wong T. Y., Tai E. S., Feranil A. B., Kuzawa C. W., Adair L. S., Taylor H. A., Borecki I. B., Gabriel S. B., Wilson J. G., Holm H., Thorsteinsdottir U., Gudnason V., Krauss R. M., Mohlke K. L., Ordovas J. M., Munroe P. B., Kooner J. S., Tall A. R., Hegele R. A., Kastelein J. J. P., Schadt E. E., Rotter J. I., Boerwinkle E., Strachan D. P., Mooser V., Stefansson K., Reilly M. P., Samani N. J., Schunkert H., Cupples L. A., Sandhu M. S., Ridker P. M., Rader D. J., Van Duijn C. M., Peltonen L., Abecasis G. R., Boehnke M., Kathiresan S., Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010 466 7307 707 713 2-s2.0-77955505564 10.1038/nature09270
144. http://circ.ahajournals.org/cgi/content/meeting
145. Rousset X., Vaisman B., Auerbach B., Krause B. R., Homan R., Stonik J., Csako G., Shamburek R., Remaley A. T., Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice. Journal of Pharmacology and Experimental Therapeutics 2010 335 1 140 148 2-s2.0-77957222802 10.1124/jpet.110.169540
146. Rousset X., Shamburek R., Vaisman B., Amar M., Remaley A. T., Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor? Current Atherosclerosis Reports 2011 13 3 249 256 2-s2.0-79955880471 10.1007/s11883-011-0171-6
147. Asada S., Kuroda M., Aoyagi Y., Fukaya Y., Tanaka S., Konno S., Tanio M., Aso M., Satoh K., Okamoto Y., Nakayama T., Saito Y., Bujo H., Ceiling culture-derived proliferative adipocytes retain high adipogenic potential suitable for use as a vehicle for gene transduction therapy. American Journal of Physiology 2011 301 1 C181 C185 2-s2.0-79959859241 10.1152/ajpcell.00080.2011
148. Rader D. J., Molecular regulation of HDL metabolism and function: implications for novel therapies. Journal of Clinical Investigation 2006 116 12 3090 3100 2-s2.0-33845320131 10.1172/JCI30163
149. Bailey D., Jahagirdar R., Gordon A., Hafiane A., Campbell S., Chatur S., Wagner G. S., Hansen H. C., Chiacchia F. S., Johansson J., Krimbou L., Wong N. C. W., Genest J., RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. Journal of the American College of Cardiology 2010 55 23 2580 2589 2-s2.0-77952713824 10.1016/j.jacc.2010.02.035
150. Gordon A., Jahagirdar R., Johannson J., RVX-208 a small molecule that induces apolipoprotein A-I production progresses to phase Ib/IIa clinical trials. Proceedings of the American College of Cardiology Scientific Sessions 2009 Orlando, Fla, USA
151. Nicholls S. J., Gordon A., Johansson J., Wolski K., Ballantyne C. M., Kastelein J. J. P., Taylor A., Borgman M., Nissen S. E., Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease: a randomized controlled trial. Journal of the American College of Cardiology 2011 57 9 1111 1119 2-s2.0-79952005101 10.1016/j.jacc.2010.11.015
152. Nicholls S. J., Gordon A., Johannson J., ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovascular Drugs and Therapy 2012 26 2 181 187
153. Shah P. K., Atherosclerosis: targeting endogenous apo A-I-a new approach for raising HDL. Nature Reviews Cardiology 2011 8 4 187 188 2-s2.0-79953188700 10.1038/nrcardio.2011.37
154. Lo Sasso G., Murzilli S., Salvatore L., Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metabolism 2010 12 2 187 193
155. Yasuda T., Grillot D., Billheimer J. T., Briand F., Delerive P., Huet S., Rader D. J., Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 4 781 786 2-s2.0-77950911589 10.1161/ATVBAHA.109.195693
156. Giannarelli C., Cimmino G., Connolly T. M., Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. European Heart Journal 2012 33 2 264 273
157. Peng D., Hiipakka R. A., Xie J. T., Dai Q., Kokontis J. M., Reardon C. A., Getz G. S., Liao S., A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR-/- mice. British Journal of Pharmacology 2011 162 8 1792 1804 2-s2.0-79953045767 10.1111/j.1476-5381.2011.01202.x
158. Rigamonti E., Helin L., Lestavel S., Mutka A. L., Lepore M., Fontaine C., Bouhlel M. A., Bultel S., Fruchart J. C., Ikonen E., Clavey V., Staels B., Chinetti-Gbaguidi G., Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circulation Research 2005 97 7 682 689 2-s2.0-26244463785 10.1161/01.RES.0000184678.43488.9f
159. Bradley M. N., Hong C., Chen M., Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. Journal of Clinical Investigation 2007 117 8 2337 2346
160. Quinet E. M., Basso M. D., Halpern A. R., Yates D. W., Steffan R. J., Clerin V., Resmini C., Keith J. C., Berrodin T. J., Feingold I., Zhong W., Hartman H. B., Evans M. J., Gardell S. J., DiBlasio-Smith E., Mounts W. M., LaVallie E. R., Wrobel J., Nambi P., Vlasuk G. P., LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. Journal of Lipid Research 2009 50 12 2358 2370 2-s2.0-70849088458 10.1194/jlr.M900037-JLR200
161. Katz A., Udata C., Ott E., Hickey L., Burczynski M. E., Burghart P., Vesterqvist O., Meng X., Safety, pharmacokinetics, and pharmacodynamics of single doses of lxr-623, a novel liver X-receptor agonist, in healthy participants. Journal of Clinical Pharmacology 2009 49 6 643 649 2-s2.0-67049144914 10.1177/0091270009335768
162. Griffett K., Solt L. A., El-Gendy B. E., Kamenecka T. M., Burris T. P., A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chemical Biology 2012 8 3 559 567
163. Mencarelli A., Fiorucci S., FXR an emerging therapeutic target for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine 2010 14 1-2 79 92 2-s2.0-77951942185 10.1111/j.1582-4934.2009.00997.x
164. Hambruch E., Miyazaki-Anzai S., Hahn U., Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. Journal of Pharmacology and Experimental Therapeutics 2012 343 3 556 567
165. Fiorucci S., Cipriani S., Baldelli F., Mencarelli A., Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Progress in Lipid Research 2010 49 2 171 185 2-s2.0-76549086983 10.1016/j.plipres.2009.11. 001
166. Al-Allaf F. A., Coutelle C., Waddington S. N., David A. L., Harbottle R., Themis M., LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. International Archives of Medicine 2010 3 1, article 36 2-s2.0-78649942440 10.1186/1755-7682-3-36
167. Grossman M., Rader D. J., Muller D. W. M., Kolansky D. M., Kozarsky I., Clark B. J., Stein E. A., Lupien P. J., Brewer H. B., Raper S. E., Wilson J. M., A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nature Medicine 1995 1 11 1148 1154 2-s2.0-0028793489
168. Plump A. S., Scott C. J., Breslow J. L., Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proceedings of the National Academy of Sciences of the United States of America 1994 91 20 9607 9611 2-s2.0-0028025262
169. Maeda N., Li H., Lee D., Oliver P., Quarfordt S. H., Osada J., Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. Journal of Biological Chemistry 1994 269 38 23610 23616 2-s2.0-0027989828
170. Gaudet D., de Wal J., Tremblay K., Déry S., van Deventer S., Freidig A., Brisson D., Méthot J., Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atherosclerosis Supplements 2010 11 1 55 60 2-s2.0-77952571307 10.1016/j.atherosclerosissup.2010.03.004
171. Gaudet D., Méthot J., Déry S., Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPL(S447X)) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Therapy 2013 20 4 361 369
172. Marquart T. J., Allen R. M., Ory D. S., Baldán A., miR-33 links SREBP-2 induction to repression of sterol transporters. Proceedings of the National Academy of Sciences of the United States of America 2010 107 12228 12232
173. Horie T., Ono K., Horiguchi M., Nishi H., Nakamura T., Nagao K., Kinoshita M., Kuwabara Y., Marusawa H., Iwanaga Y., Hasegawa K., Yokode M., Kimura T., Kita T., MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proceedings of the National Academy of Sciences of the United States of America 2010 107 40 17321 17326 2-s2.0-78049295975 10.1073/pnas.1008499107